Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
On November 18, 2021, AbbVie published a literature review in Advances in Therapy, outlining the economic benefits of achieving clinical remission in rheumatoid arthritis (RA). The review indicates that remission is linked to substantial cost savings: 19%-52% in direct medical costs and 37%-75% in indirect costs. Patients with sustained remission experience fewer disease flares and require less medical intervention. The findings emphasize the importance of treatment strategies aimed at reaching remission, as recommended by clinical guidelines. The review analyzed 16 studies from various countries, emphasizing the crucial role of remission in enhancing patient quality of life.
AbbVie announced that the European Commission has approved SKYRIZI® (risankizumab) for treating adults with active psoriatic arthritis who have not responded adequately to other treatments. This approval, based on Phase 3 clinical trials KEEPsAKE-1 and KEEPsAKE-2, marks the second indication for SKYRIZI in the EU. The studies reported significant improvements in patient outcomes, with 57.3% and 51.3% of participants achieving the primary efficacy endpoint at week 24, compared to placebo. The safety profile aligns with previous data, showing no new risks.
Summary not available.
AbbVie has extended its collaboration with the University of Chicago through 2025 to bolster preclinical oncology research. This partnership has yielded insights into biomarkers and novel drug delivery strategies enhancing anti-tumor immune responses. The extension aims to further accelerate medical research in oncology, with AbbVie gaining exclusive licensing rights to certain discoveries. AbbVie emphasizes the collaboration's potential impact on public health and aims to leverage findings for developing innovative cancer therapies.
AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on November 17, 2021, at 8:30 a.m. Central time. Key executives including Dr. Michael Severino, Robert A. Michael, and Jeffrey R. Stewart will present at the event. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later the same day. AbbVie's mission focuses on delivering innovative medicines in various therapeutic areas, including immunology, oncology, and more.
AbbVie (NYSE: ABBV) reported promising results from post-hoc analyses of the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials, demonstrating that upadacitinib (RINVOQ®) provided greater clinical responses for active psoriatic arthritis (PsA) patients with axial involvement compared to both placebo and HUMIRA® at 24 weeks. Specifically, 69.8% of patients on upadacitinib achieved clinically important improvement. Safety profiles were consistent with previous studies, with no new risks identified. Upadacitinib is currently under FDA review for PsA treatment.
Summary not available.
NORTH CHICAGO, Ill., Nov. 8, 2021 – Allergan, part of AbbVie (NYSE: ABBV), will present new analyses of VUITYTM (pilocarpine HCl) and DURYSTA® (bimatoprost) at the AAO 2021 Annual Meeting (Nov. 12-15). VUITY is the first FDA-approved eye drop for presbyopia, aiding nearly 128 million U.S. adults. DURYSTA aims to reduce intraocular pressure in glaucoma patients. Key presentations include pooled safety and efficacy data and real-world studies of glaucoma treatment. This reflects AbbVie's commitment to advancing eye care.
AbbVie presented integrated data from two Phase 3 trials, KEEPsAKE 1 and KEEPsAKE 2, showing that treatment with risankizumab (SKYRIZI) significantly improved signs and symptoms of psoriatic arthritis (PsA) after 24 weeks compared to placebo. Patients receiving risankizumab achieved an ACR20 response rate of 55.5% versus 31.3% for placebo. No new safety signals were reported, with serious treatment-emergent adverse events at 3.0% for risankizumab and 4.4% for placebo. Regulatory reviews for approval in the U.S. and EU are ongoing.
Genmab A/S (GMAB) announced several abstract presentations at the 63rd Annual ASH Meeting, showcasing the efficacy of epcoritamab (DuoBody®-CD3xCD20) for treating B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Over 20 abstracts from Genmab and its partners, including AbbVie (ABBV) and Janssen, will be shared, highlighting clinical trial results. A virtual R&D Update and ASH Data Review is scheduled for December 14, focusing on these advancements in oncology.